新聞資訊
您當(dāng)前的位置:首頁 > 新聞資訊 > 行業(yè)動(dòng)態(tài)

國(guó)際專家共識(shí):體外反搏成為心血管康復(fù)處方

更新時(shí)間:2019-12-18 14:32:27 關(guān)鍵詞:體外反搏,體外反搏治療儀

國(guó)際專家共識(shí):體外反搏成為心血管康復(fù)處方

International Expert Consensus: EECP as Prescription for Cardiovascular Rehabilitation

 

正在北京國(guó)家會(huì)議中心隆重舉辦的第二十四屆長(zhǎng)城國(guó)際心臟病學(xué)會(huì)議 | 亞太心臟大會(huì) 2013GW-ICC & APHC)暨第三屆國(guó)際體外反搏學(xué)術(shù)交流會(huì)于1011日在北京召開《心血管康復(fù)體外反搏處方國(guó)際專家共識(shí)討論會(huì)》。來自中國(guó)、美國(guó)、英國(guó)、土耳其、印度、俄羅斯,以及香港等30多個(gè)國(guó)家和地區(qū)全球體外反搏核心專家出席會(huì)議。大會(huì)由著名心血管專家胡大一教授、著名體外反搏專家伍貴富教授、JOHN CK HUI教授(美國(guó))擔(dān)任大會(huì)主席并主持討論。來自世界各地的專家們各抒己見,充分表達(dá)了自己的學(xué)術(shù)觀點(diǎn)。一致確認(rèn):體外反搏歷經(jīng)四十年的理論研究、臨床實(shí)踐及技術(shù)研發(fā)早已被實(shí)踐證明是一種既能體現(xiàn)治療價(jià)值,又能貫通慢性心血管疾病一級(jí)和二級(jí)預(yù)防的,具有鮮明中國(guó)特色的傳統(tǒng)技術(shù);體外反搏是保護(hù)血管內(nèi)皮細(xì)胞,促進(jìn)損傷血管內(nèi)膜結(jié)構(gòu)與功能修復(fù)的作用,為心血管疾病預(yù)防與康復(fù)提供了最適宜的非藥物干預(yù)手段。對(duì)此,全球體外反搏核心專家達(dá)成了共識(shí):體外反搏將成為心血管康復(fù)處方。這就意味著心血管患者有了一個(gè)行之有效的、無創(chuàng)傷性的康復(fù)途徑,這將極大的有利于一、二期心血管疾病的預(yù)防與治療。更是人類健康的福音。

The EECP as Prescription for Cardiovascular Rehabilitation Expert Consensus Meeting was held on Oct. 11th, during the event of the 24th Great Wall International Congress of Cardiology, Asia Pacific Heart Congress 2013 (GW-ICC & APHC), and the 3rd International EECP Symposium in Beijing. Hosted by distinguished professor HU Da-yi, and attended by keynote experts on EECP from over 30 countries and regions around the globe, it was as a great opportunity for a roundtable discussion for different academic viewpoints. Consensus was reached that through four decades of basic research, clinical practice and technological development, EECP is proven to be a valuable therapeutic modality for both primary and secondary prevention for cardiovascular diseases. By protecting and restoring endothelial structural and functional integrity, EECP is as an optimal non-pharmacological intervention effective not only for treatment of diseases, but also for rehabilitation.In other words, EECP is expected to benefit as a “prescription” for cardiovascular rehabilitation. This is good news for patientsburdened with cardiovascular diseases.